Antiangiogenic Therapy for Advanced Gastric Cancer - Update for Oncologists
RELEASE AND EXPIRATION
Date of original release: June 15, 2015
Date of expiration: June 14, 2016
CME Course Code: 2015Gastric
This activity is designed for oncologists and primary care physicians who treat patients with gastric cancer.
PROGRAM LEARNING OBJECTIVES
At the completion of this activity, participants should be able to:
- Summarize the current clinical progress of targeted therapies in the management of advanced gastric cancer in early and late stage clinical trials.
- Explain current clinical challenges in the management of advanced gastric cancer
- Interpret the outcome data from recent well-designed scientific and clinical studies of protocols studying new-targeted therapies.
- Integrate side effect management into the long term management of patients with advanced gastric cancer.
- Improve understanding of current targeted therapies with the associated pathways and mechanisms in the treatment of advanced gastric cancer.
This activity is designed to address the following ABMS / IOM competencies:
Patient Care and Medical Knowledge
William W. Li, M.D., President, the Angiogenesis Foundation
Harry H. Yoon, M.D., Assistant Professor of Oncology, Mayo Clinic College of Medicine
Cine-Med adheres to accreditation requirements regarding industry support of continuing medical education. Disclosure of the planning committee and faculty's commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.
All Cine-Med employees in control of content have indicated that they have no relevant financial relationships to disclose.
FACULTY DISCLOSURE SUMMARY
William W. Li, M.D. President, the Angiogenesis Foundation, Editor-in-Chief
Dr. Li has nothing to disclose with regard to commercial interests.
Harry H. Yoon, M.D. Assistant Professor of Oncology, Mayo Clinic College of Medicine, Editor
Dr. Yoon has received research grant support from Lilly Oncology and Genentech/Roche.
He has also acted on advisory boards for Lilly Oncology and FivePrime.
NON ENDORSEMENT STATEMENT
Cine-Med verifies that sound education principles have been demonstrated in the development of this educational offering as evidenced by the review of its objectives, teaching plan, faculty, and activity evaluation process. Cine-Med does not endorse or support the actual opinions or material content as presented by the speaker(s) and/or sponsoring organization.
This activity has been planned and implemented by Ciné-Med and the Angiogenesis Foundation. Ciné-Med is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Ciné-Med designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity is being supported in part by an educational grant from:
Lilly USA, LLC